Login / Signup

E2730, an uncompetitive GABA transporter-1 inhibitor, suppresses epileptic seizures in a rat model of chronic mesial temporal lobe epilepsy.

Idrish AliJuliana C SilvaPablo Miguel Casillas-EspinosaEmma BraineGlenn R YamakawaMatthew R HudsonRhys D BradyBrendan MajorPeravina ThergarajanMohammad B HaskaliDavid K WrightBianca JuppLucy E VivashSandy R ShultzRichelle MychasiukPatrick KwanNigel Charles JonesKazuyuki FukushimaPallavi SachdevJocelyn Y ChengTerence J O'Brien
Published in: Epilepsia (2023)
This study shows that continuous subcutaneous infusion of E2730 over 7 days results in a marked, dose-dependent suppression of spontaneous recurrent seizures, with minimal adverse neurological effects, in a rat model of chronic MTLE. E2730 shows strong promise as an effective new ASM to be translated into clinical trials.
Keyphrases
  • temporal lobe epilepsy
  • clinical trial
  • signaling pathway
  • randomized controlled trial
  • big data
  • artificial intelligence
  • adverse drug
  • open label